Norris Medicines Limited has submitted a regulatory disclosure to BSE Limited regarding an upcoming board meeting. The meeting of the Board of Directors is scheduled to be held on Friday, 14th August, 2026 at the company's registered office at Plot No.801/P, GIDC, Ankleshwar, Gujarat, 393002.
The board will consider and approve the following business items:
- Un-audited Financial Results for the quarter ended 30th June, 2026 along with Limited Review Report
- Any other business with permission of Chair
The disclosure also confirms that the Trading Window for dealing in securities of the Company has been closed since July 01, 2026 in accordance with the Company's Code of Conduct for Prevention of Insider Trading and SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will remain closed until Forty-Eight (48) hours after the declaration of Un-audited financial results for the quarter ended June 30, 2026 on the Stock Exchange.
The intimation is made under regulation 29 of SEBI Listing Obligation and Disclosure Requirements, 2015 and is signed by Vimal Shah, Director (DIN: 01506655) of Norris Medicines Limited.